REGN vs TERN · P/E 14, rev $14.34B vs $6.12B cap
Regeneron Pharmaceuticals Inc (REGN) versus Terns Pharmaceuticals Inc (TERN) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Terns Pharmaceuticals Inc (TERN) is a biotechnology company listed on NASDAQ.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported TERN revenue for 2022-12-31 was $0. Net income was -$60.3M. TERN currently screens at market cap $6.12B.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. TERN currently screens at market cap $6.12B.
Not investment advice. Open the REGN and TERN stock pages for the full models.
Not investment advice.